The BCL-2/BCL-XL inhibitors ABT-737, ABT-263, and venetoclax induce apoptosis in vitro and in vivo in ALL subsets, including KMT2A-rearranged and TCF3-HLF ALL leukemia xenografts and human lymphoid tumors that overexpress BCL-2 [18,20,21,22]. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.